| Today’s Big NewsOct 11, 2023 |
| By Eric Sagonowsky,Fraiser Kansteiner Just two weeks after Biogen completed its buyout of Reata Pharmaceuticals, the combined company is trimming its staff. Reata staffers who worked in roles that are already covered at Biogen are losing their jobs. |
|
|
|
By Annalee Armstrong There’s a lot of risk inherent in biotech investment, but a new report suggests that an increasingly safe bet is one of the hottest areas of drug development: cell and gene therapy. |
By Conor Hale As more and more medical technologies are being built on artificial intelligence and machine learning, the FDA is enlisting a new panel of outside experts to help them get deeper into the weeds. |
By Annalee Armstrong Things were going pretty well in the NASH landscape with Madrigal Therapeutics finally submitting a request to approve a treatment, but yesterday the space came crashing back down to reality with the failure of Akero Therapeutics’ med. |
|
Wednesday, October 18, 2023 | 11am ET / 8am PT Join industry experts for an exciting glimpse into the future of pharmaceutical innovation! Gain a comprehensive understanding of the latest strategies in organofluorine-based drug synthesis and learn key insights for staying ahead of the curve in this rapidly evolving landscape. Register now. 
|
|
By Andrea Park Regulators in the EU are said to be on the verge of handing down an order forcing Illumina to divest Grail, according to multiple reports this week, following a yearslong antitrust battle that’s stretched across the Atlantic. |
By Fraiser Kansteiner For a study weighing the injectable semaglutide in chronic kidney disease, an early end appears to give Novo Nordisk cause to celebrate. |
By Gabrielle Masson As Federation Bio fades, Kanvas Biosciences has snapped up two of the biotech’s assets as well as its microbial library and the company’s chief scientific officer Lee Swem, Ph.D., to lead program development. |
By Andrea Park A year after unveiling its first blood test aimed at spotting the signs of a range of neurodegenerative diseases, Labcorp is ramping up its offerings in that realm with the launch of a new, Alzheimer’s disease-specific test. |
By Kevin Dunleavy GSK resolved a group of claims in California over heartburn medication Zantac. But the company is hardly out of the woods in the wide-ranging litigation. |
By Nick Paul Taylor Sana Biotechnology is restructuring and narrowing its focus for the second time in 11 months. With its stock in the doldrums, the cell engineering biotech is pulling back from its in vivo delivery platform and reducing its head count by 29% to stretch its cash runway deeper into 2025. |
By Andrea Park In recent years, much of Haemonetics’ focus has been on building out a portfolio of devices for interventional cardiology procedures, and its latest M&A move continues that trend. |
By Zoey Becker In a phase 3 trial testing the two forms over 24 weeks, the subcutaneous drug measured up to the IV version, Roche said. An approval for the subcutaneous version would open the door to broader usage. |
By Fraiser Kansteiner With observations ranging from dirty packing rooms to incomplete lab control records, Spectrum Laboratory Products’ new FDA manufacturing write-up reads like a guide on what not to do when producing drug ingredients. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business.Register now! .png)
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
